We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
+31.11%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$183M
Cap. Flow
+$148M
Cap. Flow %
52.75%
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$89.1M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$59.3M

Top Sells

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$4

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
1
Tectonic Therapeutic
TECX
$690M
$84.6M 30.09%
+246,860
New +$89.1M
FTSV
2
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$61.1M 21.72%
+3,816,951
New +$59.3M
NSTG
3
DELISTED
NanoString Technologies, Inc.
NSTG
$54.2M 19.27%
3,959,440
– –
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$53.3M 18.95%
273,077
– –
VERO
5
DELISTED
Venus Concept
VERO
$12.4M 4.41%
1,442
– –
VBIV
6
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.4M 2.63%
89,701
– –
EPIX
7
DELISTED
ESSA Pharma
EPIX
$6.32M 2.25%
1,668,560
-1
-0% -$4
ATXS
8
DELISTED
Astria Therapeutics
ATXS
$1.93M 0.68%
33,470
– –

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q2 2018 Portfolio in Review

As of Q2 2018, Clarus Ventures held 8 positions worth $281M, up 188% from $97.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures deployed $148M of net new capital in Q2 2018, opening 2 new positions. Its largest new stake was Tectonic Therapeutic: 246,860 shares worth $84.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ESSA Pharma, an estimated $4 trimmed.

  • Clarus Ventures's largest Q2 2018 buy was Tectonic Therapeutic: 246,860 shares worth $84.6M.
  • Clarus Ventures's biggest Q2 2018 reduction was ESSA Pharma, cutting an estimated $4.
  • Clarus Ventures's ten largest holdings make up 100% of its $281M portfolio in Q2 2018.
  • Clarus Ventures opened 2 new positions and closed 0 in Q2 2018.
  • Clarus Ventures's portfolio value rose 188% quarter-over-quarter to $281M.

Based on Clarus Ventures's 13F filing for Q2 2018, filed 14 Aug 2018.